Proposal number Study Sponsor(s) Title Institution Lead researcher  
611GSKLong-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Airways Group, at St George's University of LondonKayleigh KewFurther Details
628GSKPredictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with PazopanibDivisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, CanadaArnoud J. Templeton, MDFurther Details
631GSKPredictors of BPH ProgressionDuke UniversityDr. Stephen Freedland, MDFurther Details
637GSKRelationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 TrialNew York University school of Medicine, NY, NYSripal BangaloreFurther Details
639GSKLow-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial DiseaseSt Luke's-Roosevelt Hospital of the Columbia University of Physicians and SurgeonsSaurav Chatterjee MDFurther Details
645GSKThe Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic HypertensionNew York Medical College-Metropolitan Hospital Center, Department of Medicine, New York, NYPartha SardarFurther Details
646GSKFactors influencing immune response and patient outcomes following influenza vaccination.Health Protection Research Group, University of NottinghamDr Subhadra RajanaiduFurther Details
647GSKAssessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical TrialsInstitute for Clinical Research and Health Policy Studies, Tufts Medical CenterDavid M. Kent, MD, MScFurther Details
651GSKDescriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children.P95 Pharmacovigilance and Epidemiology ServicesThomas VerstraetenFurther Details
653GSKFunctional Estimation of Interventional EffectsDepartment of Economics, Indiana University, Bloomington, Professor Sungkyunkwan University, Professor of EconomicsJoon ParkFurther Details
654GSK, ViiVDevelopment of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7)Institute of Pharmacy, Clinical Pharmacy, University of Bonn, GermanyUlrich JaehdeFurther Details
657GSKUse of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trialsMcMaster UniversityHolger Schunemann, MD, MSc, PhDFurther Details
668GSKAssociations between antihypertensive drugs and patterns of blood pressure changes: a strategy to reduce the burden of anti-VEGF induced hypertensionFlinders University, School of Medicine, Adelaide, Australia; Southern Adelaide Health Network, Adelaide, AustraliaArduino A MangoniFurther Details
669GSKA multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes.University of AdelaideJon JureidiniFurther Details
672GSKThe Development of Toxicity Prediction Tools to Assist Oncologists in the Management of Adverse Events in Patients Receiving Treatment with LapatinibMemorial Sloan-Kettering Cancer CenterDr. Mario LacoutureFurther Details
674GSKAntiepileptic drug monotherapy for epilepsy: an overview of systematic reviews and network meta-analysisUniversity of LiverpoolAntony MarsonFurther Details
675NovartisValidation study on magnitude of tumorshrinkage as a prognostic markerMedical School Hannover Hematologgy, hemostasis, oncology and stemcelltransplantation Carl-Neuberg-Str. 1 30627 Hannover, GermanyViktor GrünwaldFurther Details
679GSKAn Epigenetic Analysis of the ALOX5 Gene Related to the Clinical Response to MontelukastUniversity of North Carolina at Chapel Hill Division of Pulmonary and Critical Care Medicine 130 Mason Farm Rd Chapel Hill NC 27599-7020Wayne H AndersonFurther Details
681GSKA randomized, double blind, placebo-controlled trial to evaluate the effect of rosiglitazone on metabolic markers in psoriasis patientsMassachusetts General HospitalAlexa B. KimballFurther Details
911GSKOutcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial DataCedars-Sinai Medical CenterLindsy Forbess, MD, MScFurther Details
918GSKOutcomes after Percutaneous Coronary Intervention in Cancer patients with Acute Coronary SyndromeNew York Medical College, New York, NY.Partha Sardar MDFurther Details
928GSKLung function and airway inflammation response after ozone exposure 0.25ppmUNC HospitalsKrista Todoric, MDFurther Details
930GSKMASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studiesNIHR Exeter Clinical Research Facility University of Exeter Medical School Barrack Road Exeter EX2 5DWProfessor Andrew Hattersley, M.D. FRSFurther Details
945ViiVTHE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTSUniversity Hospital Ramón y CAjalSantiago MorenoFurther Details
946GSK, RocheAssessing models for changes in tumour size over time and how they relate to survival times.Division of Mathematics, University of Dundee, Dundee, UK.Raluca EftimieFurther Details
951GSKOptimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopeniaThe University of JordanMohammad SalehFurther Details
955GSKA study of subgroup identification and micro aggregationNational Institute of Statistical Sciences www.niss.orgS. Stanley YoungFurther Details
956RocheBone Quality ProjectUniversity of California, San FranciscoDennis M. BlackFurther Details
976GSK5-alpha reductase inhibitor use and risk of lung cancerDepartment of Internal Medicine University of Manitoba Department of Medical Oncology and Hematology Cancercare ManitobaMarshall PitzFurther Details
977GSKThe implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculationUniversity of Zurich Institute of Social and Preventive Medicine Hirschengraben 84 CH-8001 ZurichMilo PuhanFurther Details
980GSKAssociation of leukotriene C4 synthase gene (rs730012, -444 A/C) polymorphism with response to leukotriene modifiers treatment in asthma patientsInstitute of Epidemiology and Preventive Medicine, National Taiwan University. Department of Family Medicine, Renai Branch, Taipei City HospitalYi-Fan WuFurther Details
982ViiVPharmacokinetic modeling of dolutegravir in HIV patients.National Brain Research Centre,Manesar,Haryana,Gurgaon,India-122050V P Subramanyam RallabandiFurther Details
988RochePhD Project: Bayesian Multivariate Network Meta-Analysis of Ordered Categorical DataSchool of Health and Related Research (ScHARR) at the University of SheffieldFabrizio MessinaFurther Details
989GSKAssessing at the participant level the applicability of clinical trials to a specific patientLister Hill National Center for Biomedical Communications, US National Library of Medicine, NIHAmos CahanFurther Details
993GSKA Spirometric Z-Score Based Reappraisal of the TORCH Study(GSK-SCO30003): Salmeterol and Fluticasone Propionate in COPD.Yale University School of MedicineCarlos A. Vaz Fragoso, MDFurther Details
995Boehringer Ingelheim, GSK, Lilly, Roche, Takeda, UCBIdentifying immune modulating patterns across diseases from open clinical trial dataInstitute for Computational Health Sciences UCSF School of Medicine Mission Hall - 550 16th St, San Francisco, CA 94158 email:Atul.Butte@ucsf.edu Phone: 415-514-0511Further Details
997GSKPredictors of Prostate Cancer Progression Among Men on Active SurveillanceDuke UniversityStephen Freedland, MDFurther Details
998GSKDetermination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosusRush University Medical CenterMeenakshi Jolly, MD, MSCPFurther Details
999Boehringer Ingelheim, GSKAssessing the Comparative Efficacy of Therapeutics for Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of Randomized TrialsThomson ReutersKristen M SweetFurther Details
1000GSKReview of fever and febrile convulsion rates in children after trivalent influenza vaccine.National Centre for Immunisation Research and Surveillance, The Children’s Hospital at WestmeadDr Jean Li-Kim-Moy, MBBS, FRACPFurther Details
1002GSKLong-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary diseaseKansas City University of Medicine & BiosciencesMichael SaraiFurther Details
1013GSKBiopsy Avoidance in Patients At Risk For Prostate Cancer and in Patients With Low Risk Prostate Cancer: Developing Tools for Personalized MedicinePrincess Margaret Cancer Centre, University Health Network, Surgical Oncology, Urologist.Girish Kilkarni, MD, PhDFurther Details
1015GSKPazopanib induced liver toxicity: incidence, pathogenesis and value of liver enzymes increase as a predictor of outcome in metastatic soft tissues sarcoma patients. A retrospective multi-centric studyDepartment of Medical Oncology University Campus Bio-Medico Via A. Del Portillo 200, 00128 Rome, ItalyBruno Vincenzi, MD, PhDFurther Details
1016GSKStatistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique.London School of Hygiene and Tropical MedicinePaul MilliganFurther Details
1020GSKGenomic prediction tools developed using phenotypes from disease progression modelsUniversity of ChicagoManish Sharma, MDFurther Details
1022NovartisPrediction of maximal work load (Wmax)in a bicycle test in patients with COPD.Dept of Respiratory Medicine & Allergology Lund University Hospital 22185 Lund, SwedenGöran ErikssonFurther Details
1028ViiVImpact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients.Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAINJosé Ramón BlancoFurther Details
1053GSKValidation of the spirometric LMS equations in the Spanish populationRespiratory department, Universitary Hospital of ArabaDr. Patricia SobradilloFurther Details
1057GSKHealth-related utility and disutility value in metastatic renal cell carcinoma patient treated with pazopanibDepartment of Urology, Seoul National University Hospital, College of Medicine Seoul National UniversityChang Wook JeongFurther Details
1058ViiVRitonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data meCentre for Health & Infectious Diseases Research Rigshospitalet, University of Copenhagen CHIP, Department of Infectious Diseases and Rheumatology, Section 2100, Finsencentret Blegdamsvej 9 DK-2100 Copenhagen Ø DenmarkAlvaro H BorgesFurther Details
1071Boehringer Ingelheim, GSKOptimising the Analysis of vascular Prevention trials (OA-Prevention)University of NottinghamFurther Details
1073GSKEnd-of-life trajectories in COPDCIRO+, centre of expertise for chronic organ failure; Maastricht University Medical Centre (MUMC+), Maastricht, the NetherlandsDr. Daisy J.A. JanssenFurther Details
1075RocheEfficacy and Safety of Bevacizumab in the Elderly Cancer Patients: Pooled Analysis of Ten Randomized Clinical TrialsDepartment of Biostatistics & Bioinformatics Duke UniversityXiaofei WangFurther Details
1078LillyNocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trialsUniversity Hospital Geelong, AustraliaSeetal DoddFurther Details
1079ViiVThe effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.Deparment of Infectious Diseases, University Hospital Ramón y Cajal, Madrid, Spaon.Sergio Serrano-Villar, MD PhDFurther Details
1084GSKStudies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials.Karolinska Institutet Department of Medicine Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), D1:00, Karolinska University Hospital, Stockholm, SwedenRonald van Vollenhoven, MD, PhDFurther Details
1085RocheOptimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis BThe University of JordanMohammad I Saleh, PhDFurther Details
1086ViiVAbacavir HLA-B*57:01 tolerance and genetic variation within the MHC.Institute for Immunology & Infectious Diseases, Discovery Way, Murdoch, WA 6150Elizabeth Phillips, MDFurther Details
1088GSKA study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants.University of North Carolina at Chapel HillJoann GruberFurther Details
1090GSKValidating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037)Fred Hutchinson Cancer Research Center; Department of Biostatistics, University of WashingtonM. Elizabeth HalloranFurther Details
1100Boehringer IngelheimSystolic blood pressure level and risk of intracerebral hemorrhage.Julius Center for Health Sciences and Primary Care UMC UtrechtJacoba P GrevingFurther Details
1103GSKA study on the possible association between antidepressant response to SSRIs and proneness for side effectsDepartment of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, SwedenElias Eriksson, MD, PhDFurther Details
1108GSKCorrelation between SF-36 PCS and MCS scores and SELENA SLEDAI activity score in SLE: a meta-anaysis.Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, SwitzerlandChaigne BenjaminFurther Details
1125LillyInitial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies.Department of Psychiatry and Psychotherapy TU-MünchenStefan LeuchtFurther Details
1128GSKEuroTARGET GWAS on sunitinib pharmacogenetics in patients with metastatic renal cell carcinomaLeiden University Medical Center (LUMC)Prof. H.J. GuchelaarFurther Details
1130GSK, UCBFactors that determine placebo response in epilepsy trialsCenter for Biostatistics Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai One Gustave Levy Place, Box 1077 New York, NY 10029Emilia BagiellaFurther Details
1132GSKCytokine patterns in anti-viral disease vaccines: a knowledge driven approachDivision of Systems Medicine Chief Department of Pediatrics Stanford UniversityAtul J. Butte, MD, PhDFurther Details
1134GSKIncidence rate and risk factors associated with Hepatocellular carcinoma development in patients with Chronic Hpatitis C and severe thrombocytopenia: the lesson from Enable studiesAO FBF e Oftalmico, Milano ItalyProf. Savino Bruno, MDFurther Details
1136TakedaCan Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab?University of MichiganPeter HigginsFurther Details
1137GSKImmunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease.Imperial College LondonRoy Anderson, PhDFurther Details
1140Boehringer IngelheimEvaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinibMD Anderson Cancer CenterJohn Heymach, MD, PhDFurther Details
1141GSKMultivariate methods for meta-analysis of vaccine studies with multiple correlated outcomesNuffield Department of Primary Care Health Sciences, University of OxfordMerryn VoyseyFurther Details
1142Boehringer Ingelheim, GSK, UCBA meta-analysis of Parkinson’s diseaseDivision of Systems Medicine Department of Pediatrics Stanford UniversityAtul ButteFurther Details
1148LillyMeta-analysis of the risk of relapse in bipolar disorderFIDMAG Germanes Hospitalàries & King’s College LondonDr. Joaquim RaduaFurther Details
1152Boehringer IngelheimAdvanced analytic methods to refine phenotyping and risk prediction among patients with atrial fibrillation in the RE-LY trialYale School of Medicine Center for Outcomes Research and EvaluationNihar Desai, MD, MPHFurther Details
1154GSKDeveloping New Outcome Measures for SLE by Deconvoluting Available DatasetsLupus Research InstitutePeter E. Lipsky, MDFurther Details
1157GSKQuality-adjusted survival analysis for patients with metastatic renal cell carcinoma treated in a phase III trial of pazopanib versus sunitinib (COMPARZ trial)Department of Urology, Seoul National University Hospital, College of Medicine Seoul National UniversityChang Wook JeongFurther Details
1159ViiVValidation of Pharmacokinetic/Viral Dynamic Modeling and Simulation using the Dolutegravir Phase IIa DatasetUniversity of Alabama at BirminghamEdward P. Acosta, Pharm.D.Further Details
1160Boehringer IngelheimDevelopment of a clinical decision support tool to identify patients at high risk of early or late bleeding complications from anticoagulationDepartment of Epidemiology and Biostatistics College of Public Health University of Georgia Athens, GA 30602Mark H. Ebell MD, MSFurther Details
1161RocheNovel approaches to the prediction of influenza complicationsDepartment of Epidemiology and Biostatistics College of Public Health University of Georgia Athens, GA 30602Mark H. EbellFurther Details
1173GSK, LillyInitial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysisInterdisciplinary Center Psychopathology and Emotion regulation, Department of Psychiatry, University Medical Center Groningen, the NetherlandsYmkje Anna de VriesFurther Details
1180GSKEvaluation of a platelet count threshold for bleeding risk in thrombocytopenic patients with chronic liver disease who undergo diagnostic and therapeutic invasive procedures.Department of Internal Medicine, University of Genoa, Genoa, Italy.Edoardo G. GianniniFurther Details
1186GSKUsing generalized pairwise comparisons to assess the benefit/risk balance of pazopanib vs sunitinib for patients with advanced or metastatic renal cell carcinomaIDDI incMarc BuyseFurther Details
1206GSKEfficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL)Interdisciplinary Center of Clinical Trials (IZKS), University Clinic of Mainz, GermanyKuhn, AnnegretFurther Details
1224GSKINTERACTION BETWEEN MENINGOCOCCAL SEROGROUP B VACCINE (BEXSERO™) AND ROUTINE INFANT VACCINES ON THE RISK OF OCCURRENCE AND RECURRENCE OF ADVERSE EVENTS FOLLOWING IMMUNIZATION.Institut National de Santé Publique du Québec(INSPQ) and Laval UniversityGaston De SerresFurther Details
1234LillyPredictors of Placebo Response in Pediatric Patients with Generalized Anxiety DisorderUniversity of CincinnatiJeffrey R. StrawnFurther Details
1236GSKCOPERNICUS re-analysisMagdi Yacoub Institute - Heart Science Centre National Heart & Lung Institute (Myocardial Function Section) Harefield Hospital Hill End Road Harefield, Middlesex, UB9 6JHJohn ClelandFurther Details
1250Boehringer Ingelheim, LillyThe relationship of treatment effects and per capita income of study countries in duloxetine trials in the treatment of depressed patientsDepartment of Psychiatry II, Ulm UniversityMarkus KoestersFurther Details
1256GSKPopulation mechanistic heamatotoxicity modeling of Dapsone in G6PD deficiency patientsHead of Department, Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine research Unit (MORU)Joel TarningFurther Details
1257GSKAn independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial dataYale University School of Medicine Yale-New Haven Hospital Center for Outcomes Research and EvaluationJoseph S. Ross, MD, MHSFurther Details
1258RocheAdvance lung cancer inflammation index (ALI) in metastatic non-squamous lung cancer: A validation studyUniversity of Texas, Houston, Texas, USASyed Hasan Raza JafriFurther Details
1273GSKPost-hoc analysis of placebo-controlled trials in children and adolescents with depressionUniversity of GothenburgElias ErikssonFurther Details
1277RocheImmunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease.Imperial College LondonRoy AndersonFurther Details
1280GSKPlacebo and nocebo effects in migraine Ver 2University Hospitals Tuebingen Dept. of Internal Medicine Tuebingen, GermanyPaul EnckFurther Details
1292LillyApplications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment SensitivityUniversity of California, Los AngelesAlex SturmFurther Details
1293RocheINCIDENCE OF BRAIN METASTASES IN METASTATIC BREAST CANCER PATIENTS RECEIVING PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: A METAANYLSIS OF FIVE PROSPECTIVE RANDOMIZED PHASE III TRIALSMedical University of Vienna, Comprehensive Cancer Center ViennaRupert BartschFurther Details
1295Boehringer Ingelheim, GSKA Swapping Method Based on Covariate Classification for Average Treatment Effect Estimation.University of Maryland, Baltimore County (UMBC), Department of Mathematics and statisticsDr. Bimal SinhaFurther Details
1307TakedaThe Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney DiseaseSeven Oaks General Hospital Renal ProgramDr. Navdeep TangriFurther Details
1316Boehringer IngelheimBlinding (Masking) and the Placebo EffectUniversity of Michigan Medical SchoolJames Brian Byrd, MD, MS, FAHA, FACCFurther Details
1320GSKUtility of a measure of Lupus Low Disease Activity State in SLEMonash HealthPei Xuan Ong (Emily)Further Details
1321GSKBone Quality ProjectUniversity of California, San FranciscoDennis M. BlackFurther Details
1322GSKComparative efficacy of different therapeutic approaches in the "naïve" patient with chronic obstructive pulmonary disease (COPD): analysis of patient-level dataNoneGiulio ParetoFurther Details
1323LillyDetection of uninformative clinics during the trial of a new drug using statistical and machine learning techniquesKKT Technology pte. ltd.Praveen DeoraniFurther Details
1326LillyReliability and Validity of the Parent Rating of Evening and Morning Behavior Scale, RevisedSUNY Upstate Medical UniversitySteven V. Faraone, Ph.D.Further Details
1331Boehringer IngelheimImpact of baseline diabetes and obesity statuses on outcomes post-ischemic strokeMedical University of South Carolina in Public Health SciencesColleen BauzaFurther Details
1335GSK, UCBInvestigation into the natural course of epilepsy and the implications on clinical trialsNINDS, National Institutes of HealthDaniel GoldenholzFurther Details
1341Boehringer IngelheimVol-PACT: Improving Volumetric CT Metrics for Precision Analysis of Clinical Trial ResultsDana-Farber Cancer Institute Harvard Medical SchoolGeoffrey R. OxnardFurther Details
1343GSKImproving the Assessment of Systemic Lupus Erythematosus Disease ActivityUniversity of Toronto, University Health NetworkZahi ToumaFurther Details
1373GSKAn exploratory analysis of headache in placebo controlled trials of paroxetine for generalized anxiety disorderUniversity of KentuckyJonathan H. Smith, M.D.Further Details
1374GSKA novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policyUniversity of PittsburghMichael M. WagnerFurther Details
1377GSKThe association between patient outcomes under two treatments (ABOUT) in cross-over trialsIDDI 30 avenue provinciale 1340 Louvain-la-Neuve BelgiumMarc Buyse, ScDFurther Details
1387GSKSex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young childrenNuffield Department of Primary Care Health Sciences, University of OxfordMerryn VoyseyFurther Details
1393RochePrognostic influence of body mass index and body weight gain in colorectal cancer patients treated with adjuvant chemotherapy: data from The AVANT studyDepartment of Internal Medicine, Seoul National University HospitalSae-Won HanFurther Details
1401SanofiUse of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trialsMcMaster UniversityHolger SchunemannFurther Details
1403ViiVMathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSMHospital General Universitario Gregorio MarañónJuan BerenguerFurther Details
1421GSKCost utility analysis comparing belimumab against rituximab in systemic lupus erythematosusWingate UniversityChris GilletteFurther Details
1422UCBDeveloping new outcome measures for SLE by deconvoluting available data setsLRIPeter E. Lipsky, MDFurther Details
1428Boehringer IngelheimEstimating absolute treatment effect of dabigatran 110 mg bid vs. 150 mg bid (vs. warfarin) for individual patients with atrial fibrillation.University Medical Center Utrecht, Utrecht, the NetherlandsFrank L.J. VisserenFurther Details
1430GSKComparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials.Department of Medicine, SolnaRonald van VollenhovenFurther Details
1433Boehringer Ingelheim, Lilly, RocheIdentification of patient subgroups with enhanced treatment response in RCTs with time-to-event outcomes: use of counterfactual restricted survival times.INSERM U1153 METHODS team, Paris, FranceLudovic TrinquartFurther Details
1450Boehringer Ingelheim, NovartisUnderstanding effectiveness of new drugs in older adults shortly after market entry.Brigham and Women's Hospital and Harvard Medical SchoolShirley V WangFurther Details
1451GSKAssessment of bias from treatment discontinuation on mortality and exacerbations in the Towards a Revolution in COPD Health (TORCH) randomized trialMcGill UniversitySamy SuissaFurther Details
1452GSKA study to determine if prior rotavirus exposure modifies the effect of rotavirus vaccines given to infants in low- and middle-income African countriesUniversity of North Carolina at Chapel HillSylvia Becker-DrepsFurther Details
1455Boehringer IngelheimPrediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attackJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the NetherlandsJacoba GrevingFurther Details
1456ViiVImpact of ongoing side effects on the efficacy of initial antiretroviral therapySt Vincent's Hospital, SydneyAndrew CarrFurther Details
1457LillyInitial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies.Department of Psychiatry and Psychotherapy TU-MünchenStefan LeuchtFurther Details
1461LillyRegression discontinuity designs to evaluate real-world clinical effectiveness: a case study of drotrecogin alphaBoston UniversityAllan J. WalkeyFurther Details
1470Takeda, UCBThe efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel diseaseGastroenterology Department, First Affiliated Hospital of Sun-YatSen University, Guangzhou, China Director, IBD Service, Sheba Medical Center, Tel-Aviv University, IsraelShomron Ben-Horin M.D.Further Details
1473RocheComparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studies(1) Department of Laboratory Medicine, National Taiwan University Hospital (2) Institute of Epidemiology and Preventive Medicine, National Taiwan UniversityKeh-Sung TsaiFurther Details
1475Boehringer IngelheimPredicting safety and efficacy of afatinib treatment of NSCLCFlinders Centre for Innovation in Cancer, Flinders University, Adelaide, AustraliaAssoc/Prof Michael SorichFurther Details
1481GSKEfficacy and safety of belimumab in childhood-onset lupusColumbia University Medical Center 630 168th St, Room PH 10-08 New York NY 10032Dr Anca Askanase MD, MPHFurther Details
1514RocheGain of quality-adjusted life year in patients with neovascular age-related macular degeneration after anti-VEGF treatmentDepartment of Ophthalmology, Seoul National University Bundang HospitalPark, Sang JunFurther Details
1526GSKAssessment of correlations among all favourable and unfavourable effects for rosiglitazone/metformin, and for metformin alone, in Type 2 diabetes.Department of Management London School of Economics Houghton Street London WC2A 2AELawrence D PhillipsFurther Details
1528GSK, Lilly, RocheA Swapping Method for Average Treatment Effect EstimationStatistics, the University of Maryland at Baltimore County (UMBC)Bimal SinhaFurther Details
1540GSKIMPROVING METHODS. Our research focus is to optimize the translation of clinical trial results into clinical practice.Brown UniversityDr. Issa DahabrehFurther Details
1541RocheItem calibration of the NEI VFQ-25 to improve future comparative research using patient-reported outcome (PRO) measures.Wilmer Eye Institute Johns Hopkins School of MedicineJudith E. GoldsteinFurther Details
1542Boehringer IngelheimOptimising the Analysis of vascular Prevention trials (OA-Prevention)University of NottinghamPhilip BathFurther Details
1558GSK, NovartisDevelopment of historical control using placebo data from pediatric epilepsy studiesUCB BioSciences, Inc 8010 Arco Corporate Drive Suite 175 Raleigh NC 27613Anthony DanielsFurther Details
1566LillyA microanalysis of symptoms and behaviors defining ADHD in adults and their response to both active medication and placeboUniversity of Utah School of Medicine Department of Psychiatry & Psychiatric & Behavioral Solutions LLCFrederick W. Reimherr MDFurther Details
1567Boehringer Ingelheim, TakedaStratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetesUniversity of Exeter Medical Scool (Honorary Consultant Physician (Diabetes) Royal Devon and Exeter Hospital)Andrew HattersleyFurther Details
1569GSKMelancholic symptoms in bipolar depression and response to lamotrigineDepartment of Psychiatry, University of Saskatchewan (U of S), Saskatchewan, CanadaDr. Evyn PetersFurther Details
1572Boehringer Ingelheim, Eisai, GSK, LillyResearch to evaluate the relation of toxicity and the relative dose intensity in phase I trials beyond cycle 1 of Molecular Targeted Agents (MTAs)Department of Breast and Medical Oncology National Cancer Center Hospital, National Cancer Center, JapanKan Yonemori, MD., PhDFurther Details
1575GSK, LillyEarly improvement in individual symptoms and response to antidepressants in patients with major depressive disorderInterdisciplinary Center Psychopathology and Emotion regulation, University Center of Psychiatry, University Medical Center Groningen, the NetherlandsYmkje Anna de VriesFurther Details
1581GSKMASTERMIND: Assessing the cost effectiveness of a stratified approach to type 2 diabetes therapyUniversity of BathProfessor Chris JennisonFurther Details
1587AstellasSex-specific efficacy of mirabegron for overactive bladder (OAB) symptoms: individual patient data meta-analysesdept. of general practice, University Medical Center Groningen, University of Groningen, the NetherlandsMarco H. Blanker, MD PhDFurther Details
1593GSKJANUVIA/JANUMET HTA Submission(Germany)MSD Sharp & Dohme GmbHDr. Rainer WokerFurther Details
1595Boehringer Ingelheim, GSK, Lilly, RocheA Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical TrialsCytel Statistical Software and Services Pvt. LtdSharayu ParanjpeFurther Details
1599RochePredictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma.Flinders UniversityMichael SorichFurther Details
1600LillyItem factor analysis of the SNAP-IV Parent Report Form: Generating item parameter estimatesUniversity of California, Los AngelesAlexandra Sturm, Ph.D.Further Details
1601SanofiIdentification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patents’ data from large randomized controlled trialsChief of Surgery, JCHO Nihonmatsu Hospital Research Professor, Fukushima Medical UniversityAkira Tsuburaya, MD PhDFurther Details
1619Boehringer IngelheimThrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke: reanalysis of ECASS III trial to assess robustness of findings across statistical modelsEBSCO Information ServicesBrian S. Alper, MD, MSPH, FAAFPFurther Details
1622ViiVA systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapiesSchool of Population and Public HealthSteve KantersFurther Details
1624LillyA Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs).The Zucker Hillside HospitalChristoph U CorrellFurther Details
1626GSKFactors associated with Prostate Cancer in Prostate Needle BiopsyUniversity of Illinois at ChicagoDaniel M. MoreiraFurther Details
1629GSKAssessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young childrenUniversity of OxfordMerryn VoyseyFurther Details
1630GSKA framework for individualized prediction of the rate and severity of asthma exacerbationsFaculty of Pharmaceutical Sciences and Faculty of Medicine, University of British ColumbiaMohsen SadatsafaviFurther Details
1633ViiVComparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study.Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAINJose Ramon BlancoFurther Details
1637Novartis1618 - Optimizing Patient Reported Outcomes by Linking Study Endpoints to Real-World BenchmarksUniversity at Buffalo, SUNYDr. Jeffrey LacknerFurther Details
1640GSKEffect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trialLewis Katz School of Medicine, Temple University.Victor KimFurther Details
1643Astellas, Lilly, Novartis, RocheDevelopment of an accurate statistical method for evaluating region-specific treatment effects in multiregional clinical trialsThe Institute of Statistical Mathematics, Research Organization of Information and Systems, Tokyo, JapanHisashi NomaFurther Details
1646LillyEffects of tumor burden change (response) on survival in mesotheliomaMayo ClinicAaron MansfieldFurther Details
1654GSK, LillyPlacebo Response in Major Depressive Disorder.University of California, Los AngelesAriana AndersonFurther Details
1660SanofiAssessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-MedicareUniversity of North Carolina at Chapel Hill, Department of Epidemiology, Gillings School of Global Public HealthJennifer L. LundFurther Details
1668RocheQuantitative Evaluation of Circadian Rhythm of Serum Glucose Level in Caucasian and Chinese Type 2 Diabetic Patients (Oct/2016)Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College HospitalPei HuFurther Details
1675LillyEfficacy and tolerability of SNRIs in depression.Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, SwedenElias ErikssonFurther Details
1684RocheANSELMA Antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy: an individual patient data meta-analysisGustave RoussyBENJAMIN BESSEFurther Details
1688NovartisTranslational data from LPT109096 to assess the impact of HER2-targeted therapies on HER-family and stem cell marker expression.National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.Denis CollinsFurther Details
1691GSKLongitudinal Concurrent and Predictive Biomarkers of Clinical Disease Severity in Systemic Lupus Erythematosus in BLISS-52/BLISS-76PfizerAustin HuangFurther Details
1692Boehringer Ingelheim, GSKPredictors of chronic obstructive pulmonary disease progressionLaboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba university, Chiba, JapanAkihiro HisakaFurther Details
1693Lilly, NovartisIdentifying Subgroups of Response to Biologics in Psoriasis using Large-scale Patient-level DataUniversity of ManchesterNophar GeifmanFurther Details
1695GSKOutcome measures and baseline predictors of response to belimumab treatment.Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, SwedenIoannis ParodisFurther Details
1702RochePooled analysis of cardiac safety of T-DM1 in HER2-positive metastatic breast cancer patientsInstitut Jules Bordet BrEAST Data Center, Brussels BelgiumEvandro de AzambujaFurther Details
1707LillyComparative Effectiveness Analysis with Data From Randomized Clinical Trials and Observational StudiesThe University of Hong Kong Duke University (Adjunct)Herbert PangFurther Details
1721Lilly, RocheImproving the evaluation of new cancer therapies to expedite patient accessUniversity of AdelaideProfessor Jonathan KarnonFurther Details
1726Takeda, UCBAssociation Between Obesity and Response to Biologic Therapy in Inflammatory Bowel DiseasesUniversity of California San DiegoSiddharth SinghFurther Details
1731GSKHost characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial dataDepartment of Epidemiology, Rollins School of Public Health, Emory UniversityJulia M. BakerFurther Details
1732Astellas, Boehringer Ingelheim, Daiichi Sankyo, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCBAssessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.University of GlasgowDr David A McAllisterFurther Details
1733RocheIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change TreatmentRady Faculty of Health Sciences, University of Manitoba Children's Hospital Research Institute of Manitoba, University of ManitobaLily LimFurther Details
1741Lilly, Novartis, RochePredictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer.Flinders UniversityDr Ashley Mark HopkinsFurther Details
1749GSK, Novartis, RocheBisphosphonates for the Treatment of Osteoporosis In Chronic Kidney Disease: an Individual Patient Level Systematic Review and Meta-AnalysesDivision of Nephrology, Department of Medicine, McMaster University, Department of Health Research Methods, Evidence and Impact, affiliated to Research St. Joseph's - HamiltonDr. David CollisterFurther Details
1752GSKSex Differences in responses to umeclidinium-vilanterol treatment in COPD patientsIstituto superiore di sanità, ItalyElisabetta StrafaceFurther Details
1758NovartisChange in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney DiseaseTufts Medical Center/Tufts Medical SchoolLesley A. Inker, MDFurther Details
1764Sanofi, TakedaPersonalized Medicine Model Builder and Evaluation for Diabetes TreatmentsQueens College, CUNY and the Wharton Business School of the University of PennsylvaniaAdam KapelnerFurther Details
1779GSKEvaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPDDivision of Infection, Immunity and Respiratory Medicine University of Manchester, UKProfessor Jørgen Vestbo DMSc FRCP FERSFurther Details
1786Lilly, Novartis, UCBThe efficacy of biologic medications in improving depressive symptoms in patients with psoriasis and PsA – Patient-level meta-analysis of randomized clinical trials dataUniversity of Toronto, Women's College Hospital, Toronto, ON, CanadaDr Lihi EderFurther Details
1794RocheA study to identify the associated factor of reported adverse event severity among HER2-positive metastatic breast cancer patient from clinical trials.Centre for Investigational New Product, National Pharmaceutical Regulatory Agency (NPRA) Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, MalaysiaOH CHEN WEIFurther Details
1808Roche, UCBLong-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysisCentro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal.José A. P. da SilvaFurther Details
1813Takeda, UCBComparative efficacy of biologics in resolving extraintestinal manifestations of inflammatory bowel disease (IBD): a systematic review and meta-analysisMayo ClinicPurna C. Kashyap, MBBSFurther Details
1816Lilly, RocheIndividual patients data based meta-analysis of randomized trials assessing the interest of molecularly targeted treatments of advanced/recurrent stomach cancer: A meta-analysis by the GASTRIC groupGustave Roussy Cancer Center Biostatistics and epidemiology dpt INSERM CESP U1018 OncoStat Meta-analysis platform 114 rue Ed Vaillant 94805 Villejuif cedex, FranceXavier PaolettiFurther Details
1819GSKINDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF ANTIDEPRESSANT TRIALS FOR MAJOR DEPRESSION IN JAPANHiroshima UniversityShigeto YamawakiFurther Details
1831GSK, Novartis, TakedaStatistical Methods Research to Compare the Performance of New Estimators of the Treatment Effect in Alzheimer’s Disease Randomized TrialsJohns Hopkins Bloomberg School of Public Health, Johns Hopkins UniversityMichael RosenblumFurther Details
1843GSKThe genetics of glycaemic response to GLP-1 receptor agonists in Type 2 diabetesUniversity of Dundee Dundee DD1 9SYEwan PearsonFurther Details
1844GSKReal World Effects of Medications for Chronic Obstructive Pulmonary DiseaseLondon School of Hygiene & Tropical medicine (LSHTM)Dr Kevin WingFurther Details
1847SanofiAntiangiogenic Second line Lung cancer Meta-Analysis (ANSELMA) - A meta-analysis on antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy.University Paris-Sud and Gustave Roussy, Department of Medicine 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France Phone: +33 (0)1 42 11 43 22 Fax: +33 (0)1 42 11 52 19Benjamin BesseFurther Details
1851RocheValidation of a Novel Outcome Instrument for SLE Clinical Trials Using Phase II Rontalizumab Study Data Set.UCSD School of MedicineKenneth KalunianFurther Details
1857GSK, NovartisComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysisKnowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s HospitalAndrea C. TriccoFurther Details
1880Boehringer Ingelheim, Eisai, Lilly, Roche, SanofiImproving the evaluation of new cancer therapies to expedite patient accessUniversity of AdelaideProfessor Jonathan KarnonFurther Details
1907GSKCritical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS.European institute of Oncology , MilanTommaso De PasFurther Details
1911Boehringer Ingelheim, Daiichi SankyoLower incidence of atrial fibrillation in NOAC treated patients without prior AFDepartment of Cardiology, Maastricht University Medical Centre, Maastricht, the NetherlandsÖmer ErkünerFurther Details
1925GSKEstablishINg the best STEp-up treatments for children with uncontrolled asthma despite Inhaled corticosteroids (EINSTEIN): A systematic review, network meta-analysis and cost effectiveness analysisUniversity of LiverpoolCatrin Tudur SmithFurther Details
1928GSKThe development of a disease progression model to describe the long-term effects of anti-diabetic medications on Hemoglobin A1CThe University of JordanMohammad SalehFurther Details
1933NovartisBenefit-harm assessment of Fingolimod: a novel methodology to inform patients with MS, industry, guideline developers and regulatory agencies on the balance of benefits and harmsUniversity of Zurich Institute of Social and Preventive Medicine Hirschengraben 84 CH-8001 ZurichAlessandra SpanuFurther Details
1934GSKUsing zanamivir trial data to evaluate baseline characteristics and disease progression by various subgroups to inform clinical development of novel therapies in hospitalized patients with influenzaGenentech, Inc., A member of the Roche GroupLesley ButlerFurther Details
1955Boehringer IngelheimDevelopment and validation of a model to predict absolute vascular risk reduction due to intensive blood-pressure targets in individual patients at baseline and after three monthsUniversity Medical Center Utrecht, Utrecht, the NetherlandsF.L.J. VisserenFurther Details
1996SanofiStatistical Methods for Causal Inference Adjusting for AdherenceSouthern Methodist University Department of Statistics University of Texas Southwestern Medical Center Department of Clinical SciencesDaniel HeitjanFurther Details
2029GSK, LillyMatching the Right Antidepressants with the Right Patients: Using Artificial Intelligence to Personalize the Treatment of DepressionDouglas Mental Health University Institute McGill UniversityGustavo TureckiFurther Details
2033Boehringer IngelheimApplying machine learning tools to personalize dabigatran treatment decisionsStanford UniversitySanjay BasuFurther Details
2036Boehringer IngelheimPrediction of bleeding events in patients with non-valvular atrial fibrillation - validation of the VTE-BLEED scoreLeiden University Medical Centre, Leiden, NetherlandsMenno V HuismanFurther Details
2056LillyBreakthrough on Antipsychotic Maintenance Medication: An Individual Participant Data Meta-Analysis.The Zucker Hillside Hospital, The Feinstein Institute of Biomedical Research Northwell HealthJose M Rubio M.D.Further Details
2069LillyEstimating the impact of different approaches to the analysis of time-to-event and longitudinal data on modelled cost-effectiveness.School of Health and Related Research (ScHARR), The University of SheffieldBen KearnsFurther Details
2074RocheAssociation between pertuzumab induced diarrhea and cutaneous rash and survival outcomes in patients with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trialInstitut Jules BordetEvandro de AzambujaFurther Details
2084GSKRelationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitationPneumology Department. Hospital Universitari Vall d'Hebron. Barcelona, SpainMarc MiravitllesFurther Details
2085GSKIdentify Systemic Lupus Erythematosus (SLE) Patients Treated with Belimumab with Reduced Severe and Severe/Moderate Flares: A Post-hoc Trial AnalysisJohns Hopkins University Bloomberg School of Public Health Department of Health Policy and Management Center for Drug Safety and Effectiveness Center for Population Health ITHongjun KanFurther Details
2087LillyEffectiveness of rhGH in Children with GHD in GeNeSIS (NCT01088412) - revisedFounder and Chief Scientific Officer, Ammonett Pharma Retired from University of Virginia after serving on faculty for 40 years as a clinical investigator, Division Chief Endocrinology and Metabolism, Chairman of the Department of MedicineMichael O. ThornerFurther Details
2099Boehringer IngelheimBlood pressure variability in PRoFESS and development of incident strokeUniversity of Utah, Department of NeurologyAdam de HavenonFurther Details
2100GSKReview of post-vaccination fever and antipyretic use and their relation to vaccine immunogenicity after quadrivalent influenza vaccine in children.National Centre for Immunisation Research and Surveillance, The Children's Hospital at WestmeadDr Jean Li-Kim-MoyFurther Details
2110LillyEffects of tumor burden change (response) on survival in mesotheliomaMayo ClinicAaron MansfieldFurther Details
5453RocheEvaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast CancerAmerican University of Beirut, Medical Center Youssef ZeidanFurther Details
5459GSKPlacebo Effects in Asthma Randomized Clinical Trials: Their Magnitudes, Causes and Potential for Improving CareThe Ottawa Hospital Research Institute, University of OttawaShawn D. AaronFurther Details
5460GSKThe evaluation of hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection against laboratory-confirmed influenza infectionsSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong.Prof Benjamin J CowlingFurther Details
5471GSKEvaluating predictors of antidepressant response or remission in children and adolescents with depressionUniversity of Maryland Baltimore, School of Pharmacy, Pharmaceutical Health Services Research DepartmentO'Mareen Spence, MPHFurther Details
5494SanofiImproving Colon Cancer Therapy Decisions by Extending Trial RepresentationDepartment of Epidemiology, University of North Carolina at Chapel HillJennifer LundFurther Details
5495Boehringer IngelheimApplying clinical trial results in clinical decision-making: Impact of a patien's baseline risk on the relative effect of an intervention strategy.University Medical Center Utrecht, Utrecht, the NetherlandsFrank L.J. VisserenFurther Details
5499RocheIncorporating biomarkers into survival models to predict patientRutgers UniversityDr. Luigi Brunetti, PharmD, MPHFurther Details
5501RocheEfficacy and Tolerability of Trastuzumab-Emtansine in Elderly Patients with Advanced Breast Cancer; A Combined Analysis Institut Jules BordetNoam PondéFurther Details
5502LillyHealth Determinants of the quality of life among children with ADHD: a structural equation modelling approachNational Research Council, Neuroscience Institute, Padova, ItalyNadia MinicuciFurther Details
5504Boehringer IngelheimEstimating Oral Anticoagulant Comparative Effectiveness in the Setting of Effect Heterogeneity: Comparing Clinical Trial Transport and Observational Epidemiologic MethodsUniversity of North Carolina at Chapel HillMichael Webster-ClarkFurther Details
5505Boehringer Ingelheim, LillyA Data-Driven Statistical/Machine Learning Analysis for Extracting Clinically Actionable Predictions of Antidepressant Treatment Outcomes with Individual Depressive SymptomsMayo Clinic, Dept. of Psychiatry and PsychologyWilliam V. BoboFurther Details
5506LillyDevelopment of a limited sampling strategy for pharmacokinetic studies with pemetrexed.Radboud University Medical CenterRob ter HeineFurther Details
5509Boehringer IngelheimStatistical methodology for the analysis of incomplete data in non-inferiority clinical trials.University of Connecticut, Department of Statistics, CT, USAYulia SidiFurther Details
5513Lilly, NovartisAssociation of sunlight intensity with Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and interactions with pharmacological treatment: A cross-sectional approach.Research Institute Brainclinics, Nijmegen, The Netherlands Utrecht University, Dept. of Experimental Psychology, Utrecht, The NetherlandsMartijn ArnsFurther Details
5515GSKImpact of HPV16/18 vaccine on HPV genotype infection and cervical precancerous lesions: an implication for cervical cancer screening strategyNational Cancer Center & Cancer Hospital, Chinese Academy of Medical SciencesFanghui ZhaoFurther Details
5521GSKImpact of HPV vaccination in preventing subsequent infection and disease after excision treatmentNational Cancer Center & Cancer Hospital, Chinese Academy of Medical SciencesFanghui ZhaoFurther Details
5525GSKNovel approaches for the analysis of SLE clinical trialsAlbert Einstein College of MedicineMimi KimFurther Details
5528Boehringer IngelheimSpirometric Z-Score Reappraisal of the UPLIFT Trial: A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseYale University School of MedicineCarlos A. Vaz Fragoso, MDFurther Details
5548Boehringer Ingelheim, Lilly, RochePredictors of exposure, therapeutic and adverse effects of targeted therapeutics used in the treatment of lung cancer.Flinders UniversityAshley HopkinsFurther Details
5549Boehringer Ingelheim, GSKModel-based meta-analysis of anticoagulant therapy based on individual patient dataLaboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan Hisaka Akihiro Further Details
5565EisaiPredictors of exposure, therapeutic and adverse effects of lenvatinib used in the treatment of advanced thyroid cancer.Flinders UniversityAshley HopkinsFurther Details
5567LillyPROCLAIM trial secondary analysis: Request for data to determine pre- and mid-treatment neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios and lymphocyte nadir values to analyze if they are predictive of survival outcome.University Hospitals Siedman Cancer Center, Case Western Reserve University, Cleveland, OHTithi BiswasFurther Details
5602RochePredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers.Flinders UniversityAshley HopkinsFurther Details
5625RocheInvestigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment responseStanford UniversityMatthew BakerFurther Details
5642GSKFEV1 decline across BMI gradient in COPD patients who were part of large randomized controlled trial over at least 3 years.Centre for Heart Lung Innovation, St Paul's Hospital and Division of Respiratory Medicine, University of British Columbia,Vancouver, BC V6Z 1Y6, Canada Don D SinFurther Details
5644GSK, Lilly, SunovionFactor analysis using the Generalisability Theory of PANSS data from clinical trials in schizophrenia and bipolar disorderUniversity Hospital Geelong, Barwon Health, Geelong, AustraliaSeetal DoddFurther Details
5652UCBEfficacy of Crohn's Disease Treatment Stratified by Disease PhenotypeUniversity of California - San FranciscoVivek RudrapatnaFurther Details
5658GSKDoes Shingrix vaccination reduces the risk of stroke?University of Antwerp & Antwerp University HospitalBenson OgunjimiFurther Details
5742Boehringer Ingelheim, GSK, NovartisComparison of the effects of dual and single bronchodilators in COPD patients relocated from group D to group B by the revised 2017 GOLD classification: a post-hoc pooled analysis of global RCTsProfessor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Head, the Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, South Korea Yeon-Mok OhFurther Details
5793Astellas, UCBPredictors of exposure, therapeutic and adverse effects of certolizumab pegol used in the treatment of rheumatoid arthritis.Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South AustraliaAhmad Y AbuhelwaFurther Details
5806GSKMelancholic depression and response to lamotrigine for the treatment of acute bipolar depression: a pooled analysis of five randomized controlled trialsDepartment of Psychiatry, College of Medicine, University of SaskatchewanDr. Evyn PetersFurther Details
5808RocheEffect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisLeiden University Medical CenterDiane van der WoudeFurther Details
5809RocheEffectiveness of anti HER2 blockade according to host immune statusGangnam Severance Hospital Department of SurgeryJoon JeongFurther Details
5814UCBCalculating the Ankylosing Spondylitis Disease Activity Score (ASDAS) in radiographic and non-radiographic axial spondyloarthritis when Patient Global Assessment (PGA) is not availableLeiden University Medical Center (LUMC)Désirée van der HeijdeFurther Details
5815GSKExamining statistical methods to allow comprehensive evaluation and presentation of adverse event data in randomised controlled trialsImperial College LondonRachel PhillipsFurther Details
5819GSKThe immunogenicity and efficacy of pneumococcal vaccines: a systematic review and network meta-analysis of individual participant data University of OxfordMerryn VoyseyFurther Details
5835GSKCombined effect of belimumab and hydroxychloroquine treatment : results from the phase 3 belimumab clinical trials in patients with SLECenter of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.Savino SciasciaFurther Details
5855GSKA clinical practice for detecting the phases of Herpes Zoster.* Athens University of Economics and Business, Department of Statistics (www.stat-athens.aueb.gr ) * Frontier Science Foundation Hellas (www.frontier-science.gr )Dimitris KarlisFurther Details
5862GSKImpact of belimumab on antiphospholipid antibodies in patients with Systemic Lupus Erythematosus1st Department of Propaedeutic and Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, GreeceKaterina ChatzidionysiouFurther Details
5865GSKHospitalized influenza clinical studies: benchmarking and refinement of clinical endpointsBiomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) Department of Health and Human Services (HHS)Kimberly ArmstrongFurther Details
5880RocheAssessing immune system correlates to individual tumour size dynamics University of Manchester, Manchester, UKDr Hitesh MistryFurther Details
5886GSKEfficacy of belimumab in patients with active systemic lupus erythematosus and concomitant antiphospholipid syndromeIstituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy.Pier Luigi MeroniFurther Details
5915GSKSLE clinical and laboratory profiling to indentify best response to belimumab: results from the phase III belimumab clinical trialsCenter of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. MD, Consultant in Clinical ImmunologySavino SciasciaFurther Details
5937RochePredictors of exposure, therapeutic and adverse effects of tocilizumab used in the treatment of rheumatoid arthritis.University of South AustraliaAhmad Y AbuhelwaFurther Details
5979LillyPredictors of exposure, therapeutic and adverse effects of baricitinib used in the treatment of rheumatoid arthritis.Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South AustraliaAhmad Y AbuhelwaFurther Details
6001LillyCan I use machine learning to build a prediction model of individual patient outcome in first episode psychosis?Institute of Mental Health & Wellbeing, University of Glasgow Honorary Specialty Registrar General Adult Psychiatry, NHS Greater Glasgow & ClydeDr Samuel LeightonFurther Details